Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes of medicines in the United States. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Theravance Biopharma Inc.

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Theravance Biopharma (TBPH) and Phreesia (PHR). Theravance Biopha...

Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (TBPH) and Phreesia (PHR)

Theravance Biopharma ( ($TBPH) ) has shared an update. On March 27, 2026, Theravance and its partner Mylan reached a settlement with Mankind Pharma...

Theravance Secures Long-Term YUPELRI Patent Litigation Settlement

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Theravance Biopharma (TBPH) and Denali Therapeutics ...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Record Date	N/A	Declaration	N/A
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	TBPH	$16.54	-0.12%	190.67K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	TBPH	$16.54	-0.1%	190.67K
3
4
5
6

TBPH

TBPH

Dividend Overview

Get Theravance Biopharma Inc. Data in Excel

Get Theravance Biopharma Inc. Data in Excel